Oppenheimer on Olema Pharmaceuticals (OLMA): "We think there’s more chapters to this story left to unfold"

March 9, 2026 9:15 AM

Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $48.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA)The analyst commented, "Roche’s ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found